Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: A multicenter retrospective trial

Jae Sook Ahn, Deok Hwan Yang, Sung Hoon Jung, Yee Soo Chae, Sang Kyun Sohn, Ho Young Yhim, Jae Yong Kwak, Se Ryeon Lee, Yeo Kyeoung Kim, Hyeoung Joon Kim, Je Jung Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effectiveness of high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) as a frontline treatment in peripheral T cell lymphomas (PTCLs) is still unclear. We retrospectively investigated the clinical outcomes of HDT/ASCT as an intensifying frontline treatment in 31 patients with newly diagnosed PTCLs. The conditioning regimen of HDT/ASCT consisted of busulfan, cyclophosphamide, and etoposide (BuCyE). At diagnosis, five (16.1 %) patients were classified as high risk according to the prognostic index for PTCL (PIT). The disease status of the patients before HDT/ASCT consisted of 23 patients (74.2 %) with complete response (CR) and eight patients (25.8 %) with partial response (PR). Six (75 %) out of eight patients with PR at pretransplantation were improved in terms of the response to CR after HDT/ASCT. At a median follow-up of 32.4 months, the 3-year probability of overall survival (OS) and progression-free survival (PFS) was 64.5 ± 8.6 %. Transplant-related mortality occurred in three patients (9.7 %), due to septic shock, hemorrhage, and delayed pneumonia, respectively. Bone marrow involvement of PTCL at diagnosis was a poor prognostic factor for OS. In conclusion, frontline HDT/ASCT with a conditioning regimen of BuCyE may be an effective and tolerable intensifying therapeutic option to improve outcomes in patients with PTCLs.

Original languageEnglish
Pages (from-to)789-797
Number of pages9
JournalAnnals of Hematology
Volume92
Issue number6
DOIs
Publication statusPublished - 2013 Jun 1

    Fingerprint

Keywords

  • Autologous
  • High-dose chemotherapy
  • Peripheral T cell lymphoma
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this